Effect of Stimulant Drugs on Social Perception

The study will improve our understanding of the "prosocial" effects of ± 3,4-Methylenedioxymethamphetamine (MDMA), relative to a prototypical stimulant, methamphetamine (MA). The investigators seek to characterize the "uniquely social" effects of MDMA.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy MDMA ('Ecstasy')

Age range

18 year–35 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

University of Chicago

Chicago, Illinois, 60637, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

High school degree
English fluency
Healthy
Has used MDMA

Exclusion criteria

Pregnant or trying to become pregnant
Any medical or psychiatry condition

Treatment and study plan

3,4-methylenedioxymethamphetamine

Drug

Participants will be given 0.75mg/kg of 1.5mg/kg MDMA

Methamphetamine

Drug

Please see above.

Primary outcomes

Responses to Affective Touch

Time frame: End of study (time 0 and approximately six weeks later)

Participants will complete an affective touch task during which time they will rate pleasantness of touch on a likert scale of 1-7, with higher scores indicating greater ratings of pleasantness

Sponsors and collaborators

Lead sponsor

University of Chicago

Other

Registry information

Acronym: ESP

Important dates

Study start: 2016
Primary completion: 2018
Study completion: 2018
First posted: Dec 31, 2018
Registry last updated: Jan 5, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed